Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Bomedemstat normalizes platelet count for essential thrombocythemia

David Ross, MD, PhD, Royal Adelaide Hospital, Adelaide, Australia, shares an update on the Phase II IMG-7289-CTP-201 trial (NCT04254978) which is investigating the lysine-specific demethylase-1 (LSD1) inhibitor bomedemstat for the treatment of patients with essential thrombocythemia who are resistant or intolerant to at least one standard of care regimen. Dr Ross gives an overview of previous trials, highlighting promising results observed in myelofibrosis, and outlines the rationale for exploring bomedemstat for essential thrombocythemia. Dr Ross reports that encouraging results have been seen so far in normalization of platelet count and comments on bomedemstat’s safety profile. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Disclosures

David Ross, MD, PhD, has received research funding and honoraria for lectures and advisory boards from Novartis and BMS/Celgene.